drug survival
French translation: "survie du médicament" / taux de rétention du traitement
| GLOSSARY ENTRY (DERIVED FROM QUESTION BELOW) | ||||||
|---|---|---|---|---|---|---|
|
| 06:16 Nov 15, 2017 |
| English to French translations [PRO] Medical - Medical (general) | |||||||
|---|---|---|---|---|---|---|---|
|
| ||||||
|  Selected response from: Daryo United Kingdom Local time: 16:09 | ||||||
Grading comment
| |||||||
| Summary of answers provided | ||||
|---|---|---|---|---|
| 5 | "survie du médicament" / taux de rétention du traitement |
| ||
| 4 -1 | survie des patients (ou des répondeurs) sous Ustekinumab |
| ||
| 3 | durée de réponse au traitement |
|
| Discussion entries: 2 | |
|---|---|
Answers
2 hrs confidence: 
peer agreement (net): -1
peer agreement (net): -1survie des patients (ou des répondeurs) sous Ustekinumab Explanation: Évolution des conditions d'initiation du traitement antirétroviral des ... https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3722501/ de J Bashi - 2010 - Cité 11 fois - Autres articles L'âge médian à la mise sous traitement était constant: 35 ans chez les femmes et ... doivent être développées pour améliorer la survie des patients sous TARV. Ustekinumab dans la maladie Crohn réfractaire aux anti-TNF : une ... www.fmcgastro.org/.../ustekinumab-dans-la-maladie-crohn-ref... Les patients qui avaient reçu de l'Ustekinumab SC pour une maladie de Crohn active dans 20 ... Le critère de jugement principal était la survie sans échec du traitement, définie comme ... La durée médiane sous Ustekinumab était de 2,2 ans. L'ustékinumab confirme son intérêt dans le traitement de la maladie ... https://www.univadis.fr/.../l-ustekinumab-confirme-son-inter... L'ustékinumab confirme son intérêt dans le traitement de la maladie de Crohn ... d'induction après une thérapie à visée curative radicale prolonge la survie ... Ainsi, 397 patients ayant obtenu une réponse sous ustekinumab ont été randomisés ... |
| ||
Notes to answerer
| |||
| Login to enter a peer comment (or grade) | |||
8 hrs confidence:
"survie du médicament" / taux de rétention du traitement Explanation: "... A recent review of the data from 19 clinical trials has shown that 5–29% of patients discontinue the anti-TNF-a agent within the 24–30-week treatment period. Adherence to treatment (also referred to as ‘drug survival’) seems to be highest for etanercept followed by adalimumab and infliximab. Data for longer treatment durations are scarce but suggest an annual drop-out rate in the range 15–25% ..." http://onlinelibrary.wiley.com/doi/10.1111/j.1365-2133.2011.... "Drug survival in rheumatoid arthritis Department of Rheumatology and 1Department of Psychology (Physical Health and Rehabilitation), Cannock Chase Hospital, Brunswick Road, Cannock, WS11 2XY, UK Accepted May 26, 2006. ... ‘Drug survival’ ***** measures the length of time a patient continues to take a particular drug *****: it is a well-recognized measure of drug effectiveness, which encompasses factors such as adverse drug reactions and side-effects, poor adherence, loss of efficacy and others. To measure drug survival, it is simply necessary to ask the patient when starting on a new medication to note the date they stop taking the medication regularly. Although drug survival has been examined in a variety of medical situations, it has not previously been extensively studied in RA. ... Drug survival is cheap and easy to measure: understanding the factors that contribute to drug survival can only add to our understanding of compliance/adherence. In this case, if we assume that drug survival is a ‘good’ outcome, we need to target our counselling at those who are older/less anxious. Given that beliefs about medications do not appear to influence drug survival, these somewhat counter-intuitive and intriguing findings challenge our approach to promoting compliance/adherence/drug survival in our rheumatology patients. http://rheumatology.oxfordjournals.org/content/45/9/1178.1.f... A ce jour il existe très peu d'informations comparant le taux de rétention de ces traitements ("survie du médicament") et les causes de leur d'arrêt, en particulier ..." http://www.rheumasearch.ch/ProjetsEnCours.html -------------------------------------------------- Note added at 8 hrs (2017-11-15 14:53:30 GMT) -------------------------------------------------- IOW how long the drug - NOT the patient will "survive" (i.e. how long the drug will keep being used by the patient) - until the patient gets bored of it, starts forgetting to take it, decides "it's no longer needed", has had enough of unpleasant sides effects etc ... -------------------------------------------------- Note added at 1 day 2 mins (2017-11-16 06:19:14 GMT) -------------------------------------------------- well explained: Dermatologie. Happy drug survival : la clé pour assurer une bonne réponse clinique à long terme La pratique quotidienne nous apprend quelque chose d’autre. Malgré l’existence d’outils d’évaluation et d’objectifs de traitement pour de nombreuses maladies importantes, le résultat à long terme dans la prise en charge de ces maladies dépend en grande partie d’une variable jusqu’ici sous-estimée, à savoir l’adhésion thérapeutique du patient. https://www.revmed.ch/RMS/2016/RMS-N-500-501/Dermatologie.-H... "survie du médicament" / "taux de rétention du traitement" two faces of the same coin one from the viewpoint of the drug (stays "alive" = keeps being used as opposed to "dead" = no one wants it) the other one from the viewpoint of the patient's behaviour. You could make a parallel with a language [or a book] being dead or alive / [= "surviving"] as long as some people keep using it / reading it - "drug survival" is not exactly some made-up weird figure of speech plucked out of thin air !!! |
| |
| Login to enter a peer comment (or grade) | ||
1 day 11 hrs confidence:
durée de réponse au traitement Explanation: en l'absence d'issue fatale dans le psoriasis c'est la "survie" du traitement qui est évoquée plutôt que la survie du patient |
| |
| Login to enter a peer comment (or grade) | ||
Login or register (free and only takes a few minutes) to participate in this question.
You will also have access to many other tools and opportunities designed for those who have language-related jobs (or are passionate about them). Participation is free and the site has a strict confidentiality policy.
KudoZ™ translation help
The KudoZ network provides a framework for translators and others to assist each other with translations or explanations of terms and short phrases.
See also:
Search millions of term translations